Abstract
Vascularization is an important step in tumour growth. Although a variety of molecules, for example, VEGF, ETS-1 or nestin have been implicated in tumour angiogenesis, the molecular mechanisms of vessel formation are not fully characterized. We showed that the Wilms' tumour suppressor WT1 activates nestin during development. Here we tested whether WT1 might also be involved in tumour angiogenesis. Endothelial WT1 expression was detected in 95% of 113 tumours of different origin. To analyse the function of WT1 in endothelial cells, we used an RNAi approach in vitro and showed that inhibition of WT1 reduces cell proliferation, migration and endothelial tube formation. On a molecular level, WT1 silencing diminished expression of the ETS-1 transcription factor. WT1 and ETS-1 shared an overlapping expression in tumour endothelia. The ETS-1 promoter was stimulated approximately 10-fold by transient co-transfection of a WT1 expression construct and WT1 bound to the ETS-1 promoter in chromatin immunoprecipitation and electrophoretic mobility shift assays. Deletion of the identified WT1-binding site abolished stimulation of the ETS-1 promoter by WT1. These findings suggest that transcriptional activation of ETS-1 by the Wilms' tumour suppressor WT1 is a crucial step in tumour vascularization via regulation of endothelial cell proliferation and migration.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aihara M, Sugawara K, Torii S, Hosaka M, Kurihara H, Saito N et al. (2004). Angiogenic endothelium-specific nestin expression is enhanced by the first intron of the nestin gene. Lab Invest 84: 1581–1592.
Amoh Y, Yang M, Li L, Reynoso J, Bouvet M, Moossa AR et al. (2005). Nestin-linked green fluorescent protein transgenic nude mouse for imaging human tumour angiogenesis. Cancer Res 65: 5352–5357.
Brown C, Gaspar J, Pettit A, Lee R, Gu X, Wang H et al. (2004). ESE-1 is a novel transcriptional mediator of angiopoietin-1 expression in the setting of inflammation. J Biol Chem 279: 12794–12803.
Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML . (2003). Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27: 612–624.
Cohen Jr MM . (2006). Vascular update: morphogenesis, tumours, malformations, and molecular dimensions. Am J Med Genet A 140: 2013–2038.
Elvert G, Kappel A, Heidenreich R, Englmeier U, Lanz S, Acker T et al. (2003). Cooperative interaction of hypoxia-inducible factor-2alpha (HIF-2alpha) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1). J Biol Chem 278: 7520–7530.
Gao X, Chen X, Taglienti M, Rumballe B, Little MH, Kreidberg JA . (2005). Angioblast-mesenchyme induction of early kidney development is mediated by Wt1 and Vegfa. Development 132: 5437–5449.
Haber DA, Buckler AJ, Glaser T, Call KM, Pelletier J, Sohn RL et al. (1990). An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumour. Cell 61: 1257–1269.
Hasegawa Y, Abe M, Yamazaki T, Niizeki O, Shiiba K, Sasaki I et al. (2004). Transcriptional regulation of human angiopoietin-2 by transcription factor Ets-1. Biochem Biophys Res Commun 316: 52–58.
Hashiya N, Jo N, Aoki M, Matsumoto K, Nakamura T, Sato Y et al. (2004). In vivo evidence of angiogenesis induced by transcription factor Ets-1: Ets-1 is located upstream of angiogenesis cascade. Circulation 109: 3035–3041.
Hohenstein P, Hastie ND . (2006). The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet 15: R196–R201.
Iwasaka C, Tanaka K, Abe M, Sato Y . (1996). Ets-1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells. J Cell Physiol 169: 522–531.
Jorcyk CL, Garrett LJ, Maroulakou IG, Watson DK, Green JE . (1997). Multiple regulatory regions control the expression of Ets-1 in the developing mouse: vascular expression conferred by intron I. Cell Mol Biol (Noisy-le-grand) 43: 211–225.
Kola I, Brookes S, Green AR, Garber R, Tymms M, Papas TS et al. (1993). The Ets1 transcription factor is widely expressed during murine embryo development and is associated with mesodermal cells involved in morphogenetic processes such as organ formation. Proc Natl Acad Sci USA 90: 7588–7592.
Labrecque L, Royal I, Surprenant DS, Patterson C, Gingras D, Beliveau R . (2003). Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. Mol Biol Cell 14: 334–347.
Mikami S, Oya M, Mizuno R, Murai M, Mukai M, Okada Y . (2006). Expression of Ets-1 in human clear cell renal cell carcinomas: implications for angiogenesis. Cancer Sci 97: 875–882.
Mokry J, Cizkova D, Filip S, Ehrmann J, Osterreicher J, Kolar Z et al. (2004). Nestin expression by newly formed human blood vessels. Stem Cells Dev 13: 658–664.
Oikawa M, Abe M, Kurosawa H, Hida W, Shirato K, Sato Y . (2001). Hypoxia induces transcription factor ETS-1 via the activity of hypoxia-inducible factor-1. Biochem Biophys Res Commun 289: 39–43.
Semenza GL . (2003). Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med 54: 17–28.
Seth A, Watson DK . (2005). ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 41: 2462–2478.
Timar J, Meszaros L, Orosz Z, Albini A, Raso E . (2005). WT1 expression in angiogenic tumours of the skin. Histopathology 47: 67–73.
Wagner KD, Wagner N, Bondke A, Nafz B, Flemming B, Theres H et al. (2002). The Wilms' tumour suppressor Wt1 is expressed in the coronary vasculature after myocardial infarction. FASEB J 16: 1117–1119.
Wagner KD, Wagner N, Wellmann S, Schley G, Bondke A, Theres H et al. (2003). Oxygen-regulated expression of the Wilms' tumour suppressor Wt1 involves hypoxia-inducible factor-1 (HIF-1). FASEB J 17: 1364–1366.
Wagner N, Wagner KD, Scholz H, Kirschner KM, Schedl A . (2006). Intermediate filament protein nestin is expressed in developing kidney and heart and might be regulated by the Wilms' tumour suppressor Wt1. Am J Physiol Regul Integr Comp Physiol 291: R779–R787.
Wagner N, Wagner KD, Theres H, Englert C, Schedl A, Scholz H . (2005). Coronary vessel development requires activation of the TrkB neurotrophin receptor by the Wilms' tumour transcription factor Wt1. Genes Dev 19: 2631–2642.
Wagner N, Wagner KD, Xing Y, Scholz H, Schedl A . (2004). The major podocyte protein nephrin is transcriptionally activated by the Wilms' tumour suppressor WT1. J Am Soc Nephrol 15: 3044–3051.
Wernert N, Raes MB, Lassalle P, Dehouck MP, Gosselin B, Vandenbunder B et al. (1992). c-Ets1 proto-oncogene is a transcription factor expressed in endothelial cells during tumour vascularisation and other forms of angiogenesis in humans. Am J Pathol 140: 119–127.
Acknowledgements
The WT1 expression constructs, the ETS-1 promoter construct and the VEGFR2 promoter construct were gifts from D Haber, D Watson and C Patterson, respectively. The human umbilical endothelial cells (HUVECs) were a gift from E Van Obberghen-Schilling. J Haudebourg helped with the tumour sections. KD Wagner and N Wagner are recipients of fellowships from INSERM and EMBO (KDW.), the Deutsche Forschungsgemeinschaft (DFG), INSERM and Fondation de France (NW). This study was supported in part by grants from the Association pour le Recherche contre le Cancer (no. 5198), EC (no. LSHG-CT-2004-005085) and INSERM AVENIR.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wagner, N., Michiels, J., Schedl, A. et al. The Wilms' tumour suppressor WT1 is involved in endothelial cell proliferation and migration: expression in tumour vessels in vivo. Oncogene 27, 3662–3672 (2008). https://doi.org/10.1038/sj.onc.1211044
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1211044
Keywords
This article is cited by
-
Mechanism of action of DSP-7888 (adegramotide/nelatimotide) Emulsion, a peptide-based therapeutic cancer vaccine with the potential to turn up the heat on non-immunoreactive tumors
Clinical and Translational Oncology (2022)
-
Relation Between Telomere and Reactive Oxygen Species in Angiogenesis
Proceedings of the National Academy of Sciences, India Section B: Biological Sciences (2022)
-
WT1 expression in vessels varies with histopathological grade in tumour-bearing and control tissue from patients with breast cancer
British Journal of Cancer (2018)
-
WT1 expression in breast cancer disrupts the epithelial/mesenchymal balance of tumour cells and correlates with the metabolic response to docetaxel
Scientific Reports (2017)
-
The density of microvessels positive for Wilms’ tumour-1 protein (WT-1) is an independent predictor of recurrence risk in meningiomas
Brain Tumor Pathology (2015)